The importance of postprandial hyperglycemia position statement of the danube MCO experts

László Barkai, Nicolae Hâncu, G. Jermendy, Maya Konstantinova, Radu Lichiardopol, Maria Moţa, Cvetalina Tankova, Natalia Temelkova, G. Winkler

Research output: Contribution to journalArticle

Abstract

Both the prevalence and incidence of type 2 diabetes are increasing worldwide and over 60% of people with T2DM develop cardiovascular disease. There are many data supporting the view that glycaemic control plays a role in reducing cardiovascular complications. The relationship between hyperglycaemia and cardiovascular disease is complex with evidence suggesting that an acute increase of glycaemia, particularly after a meal, may have a direct detrimental effect on cardiovascular disease. Although control of fasting hyperglycaemia is necessary, it is usually insufficient to obtain optimal glycaemic control. A growing body of evidence suggests that reducing post meal plasma glucose excursions is as important, or perhaps more important for achieving HbA1c goals. New classes of therapies for managing post meal plasma glucose in people with diabetes (glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors) have shown significant benefits in reducing post meal plasma glucose excursions and lowering HbA1c. The individual properties of the various GLP.1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalRomanian Journal of Diabetes, Nutrition and Metabolic Diseases
Volume22
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Hyperglycemia
Meals
Cardiovascular Diseases
Glucose
Type 2 Diabetes Mellitus
Dipeptidyl-Peptidase IV Inhibitors
Incretins
Fasting
MCO
Incidence
Therapeutics

Keywords

  • Cardiovascular disease
  • GLP-1 receptor agonists
  • Postprandial hyperglycemia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The importance of postprandial hyperglycemia position statement of the danube MCO experts. / Barkai, László; Hâncu, Nicolae; Jermendy, G.; Konstantinova, Maya; Lichiardopol, Radu; Moţa, Maria; Tankova, Cvetalina; Temelkova, Natalia; Winkler, G.

In: Romanian Journal of Diabetes, Nutrition and Metabolic Diseases, Vol. 22, No. 1, 2015, p. 83-88.

Research output: Contribution to journalArticle

Barkai, László ; Hâncu, Nicolae ; Jermendy, G. ; Konstantinova, Maya ; Lichiardopol, Radu ; Moţa, Maria ; Tankova, Cvetalina ; Temelkova, Natalia ; Winkler, G. / The importance of postprandial hyperglycemia position statement of the danube MCO experts. In: Romanian Journal of Diabetes, Nutrition and Metabolic Diseases. 2015 ; Vol. 22, No. 1. pp. 83-88.
@article{2664be9a9afc4443be27ece4ee31bdd9,
title = "The importance of postprandial hyperglycemia position statement of the danube MCO experts",
abstract = "Both the prevalence and incidence of type 2 diabetes are increasing worldwide and over 60{\%} of people with T2DM develop cardiovascular disease. There are many data supporting the view that glycaemic control plays a role in reducing cardiovascular complications. The relationship between hyperglycaemia and cardiovascular disease is complex with evidence suggesting that an acute increase of glycaemia, particularly after a meal, may have a direct detrimental effect on cardiovascular disease. Although control of fasting hyperglycaemia is necessary, it is usually insufficient to obtain optimal glycaemic control. A growing body of evidence suggests that reducing post meal plasma glucose excursions is as important, or perhaps more important for achieving HbA1c goals. New classes of therapies for managing post meal plasma glucose in people with diabetes (glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors) have shown significant benefits in reducing post meal plasma glucose excursions and lowering HbA1c. The individual properties of the various GLP.1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.",
keywords = "Cardiovascular disease, GLP-1 receptor agonists, Postprandial hyperglycemia",
author = "L{\'a}szl{\'o} Barkai and Nicolae H{\^a}ncu and G. Jermendy and Maya Konstantinova and Radu Lichiardopol and Maria Moţa and Cvetalina Tankova and Natalia Temelkova and G. Winkler",
year = "2015",
doi = "10.1515/rjdnmd-2015-0011",
language = "English",
volume = "22",
pages = "83--88",
journal = "Romanian Journal of Diabetes, Nutrition and Metabolic Diseases",
issn = "1583-8609",
publisher = "Versita",
number = "1",

}

TY - JOUR

T1 - The importance of postprandial hyperglycemia position statement of the danube MCO experts

AU - Barkai, László

AU - Hâncu, Nicolae

AU - Jermendy, G.

AU - Konstantinova, Maya

AU - Lichiardopol, Radu

AU - Moţa, Maria

AU - Tankova, Cvetalina

AU - Temelkova, Natalia

AU - Winkler, G.

PY - 2015

Y1 - 2015

N2 - Both the prevalence and incidence of type 2 diabetes are increasing worldwide and over 60% of people with T2DM develop cardiovascular disease. There are many data supporting the view that glycaemic control plays a role in reducing cardiovascular complications. The relationship between hyperglycaemia and cardiovascular disease is complex with evidence suggesting that an acute increase of glycaemia, particularly after a meal, may have a direct detrimental effect on cardiovascular disease. Although control of fasting hyperglycaemia is necessary, it is usually insufficient to obtain optimal glycaemic control. A growing body of evidence suggests that reducing post meal plasma glucose excursions is as important, or perhaps more important for achieving HbA1c goals. New classes of therapies for managing post meal plasma glucose in people with diabetes (glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors) have shown significant benefits in reducing post meal plasma glucose excursions and lowering HbA1c. The individual properties of the various GLP.1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.

AB - Both the prevalence and incidence of type 2 diabetes are increasing worldwide and over 60% of people with T2DM develop cardiovascular disease. There are many data supporting the view that glycaemic control plays a role in reducing cardiovascular complications. The relationship between hyperglycaemia and cardiovascular disease is complex with evidence suggesting that an acute increase of glycaemia, particularly after a meal, may have a direct detrimental effect on cardiovascular disease. Although control of fasting hyperglycaemia is necessary, it is usually insufficient to obtain optimal glycaemic control. A growing body of evidence suggests that reducing post meal plasma glucose excursions is as important, or perhaps more important for achieving HbA1c goals. New classes of therapies for managing post meal plasma glucose in people with diabetes (glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors) have shown significant benefits in reducing post meal plasma glucose excursions and lowering HbA1c. The individual properties of the various GLP.1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.

KW - Cardiovascular disease

KW - GLP-1 receptor agonists

KW - Postprandial hyperglycemia

UR - http://www.scopus.com/inward/record.url?scp=84941343896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941343896&partnerID=8YFLogxK

U2 - 10.1515/rjdnmd-2015-0011

DO - 10.1515/rjdnmd-2015-0011

M3 - Article

AN - SCOPUS:84941343896

VL - 22

SP - 83

EP - 88

JO - Romanian Journal of Diabetes, Nutrition and Metabolic Diseases

JF - Romanian Journal of Diabetes, Nutrition and Metabolic Diseases

SN - 1583-8609

IS - 1

ER -